Following the FDA's recommendation that COVID-19 vaccine manufacturers continue to work on their booster products in order to counter new subvariants, Moderna's omicron-containing bivalent booster has show promising signs in clinical trials. 

Clinical Trials fulfil a vital role in the production of COVID-19 vaccines (and drugs in general), and the likes of Moderna, Pfizer-BioNTech and Janssen/J&J are pushing forward with the US government wanting the boosters to be available by the fall of this year.